[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medical University of South Carolina\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":600},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,155,0,25,[9,49,76,94,114,132,160,182,207,228,249,267,292,316,335,361,388,418,442,464,489,512,536,559,576],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100053310",false,"NCT07226011","Accelerated High-Dose tDCS for Depression","Accelerated High-Dose tDCS for Depression: An Open-Label Outpatient Pilot Study","Inclusion Criteria:\n\n* Ages 18-70.\n* Current MDD diagnosis (MINI v7).\n* Baseline PHQ-9 \\> 9.\n* Capacity to consent\n* Fluent English.\n\nExclusion Criteria:\n\n* Bipolar or psychotic disorder\n* Primary anxiety disorders without concomitant major depression as defined above\n* Current significant suicidal ideation or behaviors require a higher level of care.\n* Use of neuromodulation therapies (e.g., ECT, TMS, VNS) within the past 6 months.\n* History of seizures, implanted cranial\u002F cardiac metal, or neurosurgery.\n* Use of medications that significantly reduce seizure threshold\n* Frequent\u002Fsevere HA\n* Personal history of head trauma, concussion, or TBI\n* Catatonic or otherwise unable to perform the consent process\n* Current alcohol or substance-use disorder (moderate-severe).\n* Any non-uniformities in the skin under the electrode site, including eczema, severe rashes, hyperhidrosis, communicable skin disorders, sensitive skin (ex. eczema, severe rashes), blisters, open wounds, burns including sunburns, cuts or irritation (e.g. due to shaving), or other skin defects or lesions, as determined by clinical personnel\n* Pregnancy (urine test required for women of childbearing potential).","ALL","18 Years","70 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","In this study, investigators are testing whether a higher dose of a non-invasive brain stimulation technique, called transcranial direct current stimulation (tDCS), can be safely used in people with depression. Participants will come to the Brain Stimulation Lab and receive mild electrical stimulation through electrodes placed on their scalp.\n\nThe study begins with a safety run-in, where the first few participants will receive stimulation at gradually increasing levels (2, 4, and 6 milliamps) while being closely monitored. If no serious side effects are found, later participants will receive repeated 6 milliamp sessions for 5 days total. Investigators will check skin comfort, mood, and overall tolerability after each session.",[27,28],"Major Depression","Major Depression Disorders",[30,31,32,33,34,35],"Depression","Nervous System","tDCS","Interventional","Brain Stimulation","Transcranial Direct Stimulation","RECRUITING","2026-07-10",{"date":39,"type":40},"2026-07-13","ACTUAL",{"date":42,"type":40},"2025-12-15",{"date":44,"type":21},"2026-10-01",{"name":46,"class":47},"Medical University of South Carolina","OTHER",1,{"id":50,"slug":4,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":70,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100054257","NCT06912685","Early Test of an Innovative Child Maltreatment (CM) Prevention Strategy","Pilot Test of an Innovative Implementation Strategy to Improve Reach, Quality, and Equity in Child Maltreatment Prevention","(CM)","Inclusion Criteria:\n\n* At least 18 years old\n* English language proficiency\n* Ability to provide informed consent for themselves\n* Has at least one child between the ages of 0-5 years old - Caregivers Only\n* Has completed at least 1 module of SafeCare since April 2021 - Caregivers Only\n* SafeCare enrollment has been completed (e.g., not currently enrolled in SafeCare). - Caregivers Only\n* Current employment at a SafeCare agency - Agency Leaders Only\n* Full- or part-time employment at a SafeCare agency - Providers Only\n* Must be fully certified to provide SafeCare services - Providers Only\n* Must be providing services for at least 6 months - Providers Only\n\nExclusion Criteria:\n\n* Evidence of significant cognitive disability, developmental delay, or pervasive developmental disorder that would prohibit capacity to consent for themselves - Caregivers Only\n* There are no primary exclusion criteria for the Providers.\n* There are no primary exclusion criteria for Agency Leaders.",true,{"count":58,"type":21},62,[24],"Millions of children are victims of maltreatment each year in the United States. Research on home visiting programs show that child maltreatment can be prevented; however, these programs struggle to reach families in need and provide high quality care. SafeCare is a sustainable and effective home visiting child maltreatment prevention program, serving over 8,000 families each year. This study will examine the feasibility and implementation of a hybrid in-person\u002Fvirtual delivery model for SafeCare with 12 home visiting providers and 40 caregivers to inform how home visiting programs are delivered to maximize reach to families, improve family outcomes, and decrease harm to children.",[62,63,64],"Parenting Intervention","Maltreatment","Prevention",[66,67,68],"Disease Prevention","Healthy Volunteer Studies","Infant","NOT_YET_RECRUITING",{"date":39,"type":40},{"date":72,"type":21},"2027-01-01",{"date":74,"type":21},"2028-01-01",{"name":46,"class":47},{"id":77,"slug":4,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":48},"100054001","NCT05725239","taVNS or TMS or Both for Depression","Synchronized Cervical or Auricular VNS With Prefrontal rTMS for Treatment Resistant Depression (TRD)","Inclusion Criteria:\n\n* 18-75 years old\n* Undergoing cervical VNS or have tried and failed two antidepressant medications in the current episode\n* Able to provide informed consent\n* English speaking and can read and write\n* 17-item Hamilton Depression Rating Scale (HAM-D) score ≥20\n* Not responding to talking therapy.\n\nExclusion Criteria:\n\n* Preexisting neurological disorders, or dementia\n* History of major head trauma\n* Life expectancy \\\u003C1 year\n* Any type of cognitive impairment that would require approval\u002Fsignature of a legal guardian\u002Frepresentative for participation\n* A score of \\>2 on question 3 of the Hamilton Depression Rating pertaining to suicidality\n* Current active suicidal intent or plan, prior attempt within the last 6 months, or who in the judgment of the investigator would be at elevated risk for suicide will be excluded\n* Patients who are pregnant will also be excluded. We will require a pregnancy test for individuals of child-bearing potential.","75 Years",{"count":84,"type":21},24,[24],"The purpose of the research is to test out a combined treatment for depression where the investigators stimulate a nerve in the ear while at the same time stimulate the brain with magnets. These treatments are called transcutaneous (through the skin) auricular (ear) vagus nerve stimulation (taVNS) and transcranial (through the skull) magnetic stimulation (TMS). For participants who already have a cervical VNS device, the investigators will not change their treatment and will use this in place of the taVNS. The investigators think this combined method might treat depressive symptoms better than either alone. This study is in person at the Institute of Psychiatry in downtown Charleston on the MUSC campus. First, participants will have a screening session and then will have 6 treatment days total where participants will receive either VNS treatment alone, TMS treatment alone, or both at the same time. The treatment that participants start with will be randomized, and they will have 2 treatment days of each combination.",[30],{"date":39,"type":40},{"date":90,"type":40},"2023-03-14",{"date":92,"type":21},"2026-07-01",{"name":46,"class":47},{"id":95,"slug":4,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":56,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":48},"100054115","NCT06373679","Switch or Quit R01","Non-cigarette Tobacco Products as Harm Reduction Tools in Smokers Who Failed to Quit With Traditional Methods","Inclusion Criteria\n\n* Adults 21+ who previously had a quit attempt using FDA-approved pharmacotherapy.\n* Interest in reducing harms from tobacco use or quitting smoking\n\nExclusion Criteria\n\n* Pregnant, breastfeeding, or trying to become pregnant.\n* Household member currently enrolled in the study\n* Planning to move out of the area within the next 7 months","21 Years",{"count":102,"type":21},225,[24],"This study evaluates whether non-cigarette tobacco products (e-cigarettes) can help smokers quit smoking as compared to traditional quit methods (nicotine replacement therapy or varenicline\u002FChantix). Participants in this study will be randomly assigned to one of two groups, then will have a choice between the offered products of that group. Participants in the e-cigarette group will have a choice of e-cigarette brand and flavor. Participants in the medication group will have choice between nicotine replacement therapy (patches and lozenges) or varenicline, also known as Chantix. Participation will last 6 months and will include weekly phone calls for the initial 7-weeks plus a 11-week phone call and a 6-month follow-up visit. Participants will also complete electronic daily diaries during the first 7-weeks.",[106,107],"Cigarette Smoking","Smoking Behaviors",{"date":39,"type":40},{"date":110,"type":40},"2024-07-10",{"date":112,"type":21},"2027-05-01",{"name":46,"class":47},{"id":115,"slug":4,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":120,"targetDuration":4,"studyType":22,"phases":122,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":126,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":48},"100053819","NCT07091968","Feasibility of a Technology-Based Intervention for Depression Referral Uptake in Cancer Survivors","Pilot Feasibility Trial to Evaluate a Technology-Enabled Approach to Enhance Depression Referral Uptake Among Cancer Survivors","Inclusion Criteria:\n\n* age \\> 18 years\n* diagnosis of cancer\n* upcoming appointment in an HCC or HCN oncology clinic within 14 days\n* English proficiency\n* ownership of a cellphone with SMS text capability.\n* elevated depressive symptoms at screening (as measured by \\> 3 on the PHQ-2)\n\nExclusion Criteria:\n\n* cognitive impairment as evaluated by attending physician\n* currently receiving counseling for depression",{"count":121,"type":21},60,[24],"Depression is very common in cancer survivors but there are challenges to linking those in need of treatment efficiently to care. In this study, investigators will test the feasibility and acceptability of a new text-based approach to connect cancer survivors with depression with care.",[125,30],"Cancer",{"date":39,"type":40},{"date":128,"type":40},"2026-01-16",{"date":130,"type":21},"2026-12",{"name":46,"class":47},{"id":133,"slug":4,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":48},"100053518","NCT07697274","Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial","Digital Intradermal Hyaluronidase for Sclerodactyly in Systemic Sclerosis","HASSc","Inclusion Criteria:\n\n* Age ≥18 and \\\u003C60 years\n* Diagnosis of systemic sclerosis\n* Presence of sclerodactyly\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Known hypersensitivity to hyaluronidase\n* Pregnancy or breastfeeding\n* Unstable systemic disease\n* Recent changes in systemic immunomodulatory therapy\n* Conditions interfering with safe digital injections","60 Years",{"count":141,"type":21},10,[143],"EARLY_PHASE1","Translational studies have demonstrated reduced hyaluronidase activity in the skin of patients with systemic sclerosis. It is thought this may contribute to the progressive fibrosis seen in this disease. Several studies have demonstrated that exogenous hyaluronidase is very effective at improving systemic sclerosis associated microstomia. Therefore, this study aims to explore hyaluronidase for systemic sclerosis associated sclerodactyly.",[146,147],"Systemic Sclerosis","Sclerodactyly",[149,150,151,152],"Hyaluronidase","Digital fibrosis","Hand function","Autoimmune disease","2026-07-08",{"date":39,"type":40},{"date":156,"type":21},"2026-09-01",{"date":158,"type":21},"2027-11",{"name":46,"class":47},{"id":161,"slug":4,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":179,"leadSponsor":181,"locationsCount":48},"100632415","NCT07513389","Omission of Postoperative Radiation in HPV-Associated Oropharyngeal Cancer Using ctHPVDNA Surveillance (OPERATION)","Omission of Immediate Postoperative Radiation in Patients With Intermediate Pathological Risk Features and Negative Two-Week Post-Operative ctHPVDNA (OPERATION Trial)","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form.\n* Stated willingness to comply with all study procedures and availability for the duration of the study.\n* Male or female, ≥ 18 years of age (no upper age limit).\n* Biopsy proven squamous cell carcinoma.\n* p16 positive (diffuse ≥ 70% tumor cell expression, with at least moderate (2\u002F3+ staining intensity).\n* NavDx positive, HPV16 TTMV only.\n* AJCC 8th edition cT0-2 N1 M0.\n* Well lateralized tonsil (\\>1 cm from midline, tonsil, base of tongue, glossotonsillar sulcus primary tumors.\n* ≤ 2 lymph nodes, each ≤ 3cm, -OR- 1 lymph node \\>3 but \\\u003C 6 cm.\n* ≤10 pack-years of cigarette smoking or no cigarette smoking for ≥ 5 years (regardless of pack years).\n* Anatomically (e.g. adequate exposure) and physically amenable to TORS per the judgement of the operating surgeon.\n* Radiologic confirmation of the absence of hematogenous metastasis within 12 weeks prior to surgery; at a minimum CT imaging of the chest. PET\u002FCT is acceptable.\n* ECOG Performance Status 0-1.\n* CBC with differential obtained within 8 weeks prior to surgery, with adequate bone marrow function defined as follows:\n\n  * Platelets ≥ 100,000 cells\u002Fmm3\n  * Hemoglobin ≥ 9.0 g\u002Fdl (Note: The use of transfusion or other intervention to achieve Hgb ≥ 9.0 g\u002Fdl is acceptable. Transfusion must be completed within 2 to 4 weeks prior to enrollment.)\n* Adequate renal and hepatic function within 8 weeks prior to surgery, defined as follows:\n\n  * Serum creatinine \\\u003C 2.0 mg\u002Fdl.\n  * Total bilirubin ≤ 1.5 x the institutional ULN.\n* Negative pregnancy test within 2 weeks prior to surgery for women of childbearing potential.\n* Eligible for platinum chemotherapy. Chemotherapy drugs allowed: cisplatin, carboplatin\u002Fpaclitaxel, carboplatin\u002Fabraxane, per treating physician (cisplatin preferred, 2nd preference carboplatin\u002Fpaclitaxel or carboplatin\u002Fabraxane).\n* For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional year after surgery per MD discretion. Acceptable forms of birth control include hormonal contraceptives (such as birth control pills, skin patch, vaginal ring, injection, and\u002For implant), intrauterine devices (IUDs), and barrier devices (such as condoms, diaphragm, cervical cap, and sponge).\n\nExclusion Criteria:\n\n* Prior history of surgery to the head and neck that in the opinion of the investigators would modify prognostic significance of pathology results.\n* Prior history of radiation therapy to the head and neck, with the exception of skin cancer treated with a small (≤ 9cm3) field with 6 - 9 MeV electron beam or 50 - 250 kVp photon beam.\n* Prior history within 5 years of cancer with the exception of:\n\n  * Basal cell carcinoma of the skin\n  * Squamous cell carcinoma of the skin, stage 1-2\n  * Prostate cancer without distant metastases (stage M0)\n  * Thyroid cancer without distant metastases (stage M0)\n* Prior history of squamous cell carcinoma of a mucosal site in the head or neck treated with surgery alone.\n* Currently taking Disease Modifying Rheumatoid Drugs (DMRDs) or immunosuppressive medication, for example as for organ transplant or multiple sclerosis.\n* Current smoker or tobacco user.\n\n  * Severe, active co-morbidity, defined as one or more of the following:\n  * Unstable angina and\u002For congestive heart failure requiring inpatient hospitalization within the last 6 months.\n  * Transmural myocardial infarction within the last 6 months.\n  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration.\n  * Chronic Obstructive Pulmonary Disease (COPD) exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\n  * Hepatic insufficiency resulting in clinical jaundice and\u002For coagulation defects.\n\n    \\--- Note, however, coagulation parameters are not required for entry into this protocol.\n  * Evidence of active systemic lupus or scleroderma.\n  * Psoriatic arthritis.\n* Known HIV positivity. HIV positive patients are known to have worse clinical outcomes especially for local, regional, and distant cancer control. This poorer prognosis is thought to be secondary to a compromised immune system. Thus, de-intensification of radiation and chemotherapy is not justifiable in this population.\n\n  \\-- Note: HIV testing at the time of enrollment is not required.\n* Subjects of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for the immediate post-op period (1-2 weeks). Females will be determined to be not of child-bearing potential with a history of hysterectomy or with postmenopausal status of \\>12 months.\n* Pregnant or breastfeeding, or expecting to conceive within the projected duration of the study, starting one month prior to screening and for one year after surgery per MD discretion.\n* Prisoners or subjects who are involuntarily incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.",{"count":167,"type":21},36,[169],"PHASE2","This single-arm Phase II trial evaluates whether omission of postoperative radiotherapy is feasible and oncologically safe in select patients with HPV-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC). Eligible patients undergo transoral robotic surgery (TORS) and are observed without adjuvant radiation if they demonstrate low or intermediate pathological risk features and have negative circulating tumor HPV DNA (ctHPVDNA) two weeks post-operatively. Patients are followed with standard clinical surveillance combined with serial ctHPVDNA testing (NavDx®) to facilitate early detection of recurrence and prompt salvage therapy as needed.",[172,173,174],"Squamous Cell Carcinoma","Human Papilloma Virus (HPV)","Oropharyngeal Squamous Cell Carcinoma (OPSCC)","2026-06-29",{"date":177,"type":40},"2026-06-30",{"date":44,"type":21},{"date":180,"type":21},"2030-07-01",{"name":46,"class":47},{"id":183,"slug":4,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":190,"phases":4,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":202,"completionDateStruct":204,"leadSponsor":206,"locationsCount":4},"100582385","NCT06862622","Neural Representations of Memory Transformation (MEM_TRANS)","Task-based Synchronous Electroencephalography and Functional Magnetic Resonance Imaging (EEG-fMRI) to Explore Neural Representations of Memory Maintenance in the Aging Brain.","Inclusion Criteria:\n\n* Age 18 years or older (80 of the final sample will be ≥60years of age)\n* Cognitively unimpaired, ambiguous, or mildly impaired cognitive function, defined as a score of ≥18 in the Montreal Cognitive Assessment (MOCA).\n* No previous stroke, brain tumor, neurodegenerative disease, or trauma to the head\n* Ability to give consent for study participation\n* Ability to perform a computer task requiring responding to visual cues and typing on a standard computer keyboard with both index and middle fingers for 30 minutes daily.\n\nExclusion Criteria:\n\n* Inability to use both index and middle fingers to type on a standard computer keyboard\n* Dementia defined as a score of \\\u003C18 in the Montreal Cognitive Assessment (MOCA)\n* Uncorrected vision, hindering perception of visual cues presented on a standard computer screen\n* Medication use at the time of study that may interfere with learning, including but not limited to carbamazepine, flunarizine, sulpiride, rivastigmine, and dextromethorphan.\n* Neuromuscular disorders that affect fine motor control of the hands.\n* Presence of neurological or psychiatric disorders\n* Presence of scalp injury or disease\n* Prior intracranial surgery\n* Prior brain radiotherapy\n* Prior history of intracranial tumor, intracranial infection, or cerebrovascular malformation\n* Metal in the head or neck\n* Contraindications to MRI (such as severe claustrophobia, implanted medical devices)",{"count":189,"type":21},40,"OBSERVATIONAL","Investigators overarching goal is to provide evidence for the link between altered spatiotemporal (where and when) neural mechanisms and the extent of changed memory maintenance in healthy older adults and to identify potential neural markers of compensatory function (cognitive resource). Investigators preliminary studies suggest that healthy older adults, compared to younger adults, benefit behaviorally from increased coupling between frontal and parietal brain waves when retrieving and updating well-consolidated visuomotor sequence memory via stronger top-down cognitive control of memory maintenance. Thus, Investigators central hypothesis is that the dynamics across cortical and subcortical regions (i.e., spatiotemporal representations) during transitions between different levels of memory stability indicate the efficiency of memory maintenance. The rationale is that while temporal and spatial neural signatures carry distinct mechanistic information, the joint definition of spatial and temporal representations will allow the differentiation of compensatory versus neurodegenerative mechanisms.",[193],"Healthy Older Adults",[195,67,196,197,198],"Aging","memory","fMRI","EEG","2026-06-21",{"date":201,"type":40},"2026-06-24",{"date":203,"type":21},"2026-08-01",{"date":205,"type":21},"2026-09-30",{"name":46,"class":47},{"id":208,"slug":4,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":4,"eligibilityCriteria":212,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":213,"targetDuration":4,"studyType":22,"phases":215,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":48},"100527459","NCT06148038","CBD for Breast Cancer Primary Tumors","A Phase 1a \"Window Trial\" of Cannabidiol (CBD) For Breast Cancer Primary Tumors","Inclusion Criteria:\n\n1. Patients who are able to consent for surgery.\n2. Histologically confirmed invasive breast cancer (stages I, II, or III) with Ki67 proliferation rate greater than or equal to 10%.\n3. Women 18 years of age or older at time of consent.\n4. Women of child-bearing potential (WOCBP) must agree to use an approved form of birth control and to have a negative pregnancy test result before registration. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) or who is not postmenopausal. Menopause is defined clinically as 12 consecutive months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n6. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 14 days prior to registration:\n\n   1. ANC ≥ 1.5 × 109\u002FL\n   2. Platelet count ≥ 100 × 109\u002FL\n   3. Hemoglobin ≥ 9 g\u002FdL\n   4. Albumin ≥ 2.5 g\u002FdL\n   5. Bilirubin ≤ 1.5 × the upper limit of normal (ULN)\n   6. AST, ALT, and alkaline phosphatase ≤ 3 × ULN\n   7. Serum creatinine ≤ 1.5 × ULN or creatinine clearance (CrCl) ≥ 40 mL\u002Fmin on the basis of measured CrCl from a 24-hour urine collection or Cockcroft-Gault\\* glomerular filtration rate estimation:\n\n      (140-age) × (weight in kg) × (0.85 if female)\n\n      72 × (serum creatinine in mg\u002FdL)\n      * The Modification of Diet in Renal Disease (Levey et al. 2006) and the Chronic Kidney Disease Epidemiology Collaboration (Levey et al. 2009) formulas for estimation of glomerular filtration rate are also acceptable.\n7. Self declared ability and capacity to comply with the study and follow-up procedures.\n8. Subjects must be scheduled for surgery no less than 5 days from the planned start of day 1 and no more than 56 days from the planned start of day 1.\n\nExclusion Criteria:\n\n1. Subjects undergoing neoadjuvant chemotherapy or neoadjuvant endocrine therapy.\n2. Known allergy to sesame. Please note the study product contains sesame oil.\n3. South Carolina State employees or anyone whose work requires THC drug testing.\n4. Patients taking drugs metabolized by cytochrome p450 including warfarin, amiodarone, levothyroxine, clobazam, lamotrigine, valproate, prednisolone, hydrocortisone, clarithromycin, itraconazole, erythromycin, fluconazole, clopidogrel, rifampin, sulfamethoxazole, any opioids, and antiepileptic medications including carbamazapine, phenytoin, and valproic acid.\n5. Self reported routine use of recreational or medicinal marijuana products, including over-the-counter CBD oil, Marinol®, Delta-8 THC, or cannabis (defined as \\> 4 times over last 30 days) or illicit drug use including opioids, cocaine, amphetamines, PCP, LSD.\n6. Self reported concurrent use of over-the-counter CBD oil, Marinol®, Delta-8 THC, or cannabis.\n7. History of allergic reactions attributed to compounds of similar chemical or biologic composition to CBD or placebo.\n8. Underlying history of epilepsy\u002F recurrent seizure disorder or unexplained seizure within past 6 months.\n9. Patients with uncontrolled cardiovascular disease defined by myocardial infarction, stroke, or transient ischemic attack, or need for coronary stent placement within past six months.\n10. Patients with a medical history of psychiatric illness or psychiatric symptoms that would prevent them from completing study procedures or would disqualify them from surgical intervention (e.g., untreated schizophrenia, bipolar disorder, or suicide ideation\u002Fattempt resulting in psychiatric hospitalization within the last 30 days).\n11. Women who are pregnant or breastfeeding.\n12. Use of blood thinners at the time of registration (warfarin, rivaroxaban, clopidogrel, and apixaban) .",{"count":214,"type":21},84,[216],"PHASE1","This is a randomized placebo controlled partially blinded window of opportunity trial. A maximum of 84 patients with invasive breast cancer will be enrolled. Patients will be randomized 2:2:1:1 to either CBD low dose, CBD high dose, matching low dose placebo, or matching high dose placebo using permuted block randomization with random block sizes of 6 or 12. The time window between CBD or placebo initiation and surgery will be between 5 and 56 days.",[219],"Breast Cancer","2026-06-17",{"date":222,"type":40},"2026-06-22",{"date":224,"type":21},"2026-09-15",{"date":226,"type":21},"2029-03-25",{"name":46,"class":47},{"id":229,"slug":4,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":16,"minAge":234,"maxAge":235,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":243,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":48},"100527162","NCT06144177","Induction in the Dark","Induction in the Dark: a Prospective Randomized Control Trial for Perioperative Pediatric Anxiety","Inclusion Criteria\n\n* Age 2 to 6 years old\n* American Society of Anesthesiologists physical status I-II\n* Outpatient elective surgical procedures\n* Undergoing general anesthesia\n* Parent or guardian willing to be present during induction\n\nExclusion Criteria\n\n* History of previous surgery\n* Fear of the dark\n* Contraindication to inhalational mask induction of general anesthesia such as allergy to inhalation medication, NPO violation, active nausea or vomiting, severe GERD, etc.\n* Severe developmental delay\n* Severe obvious, preoperative anxiety\n* Patients currently using psychiatric medications\n* Non-English speaking","2 Years","6 Years",{"count":237,"type":21},240,[239],"PHASE4","This study will enroll children ages 2-6 who are undergoing an elective outpatient surgical procedure under general anesthesia. They will be randomized to one of the following groups and assessed for preoperative anxiety, mask acceptance, and behavioral changes in the following week.\n\n1. darkened room and star projector with parental presence;\n2. preoperative midazolam 0.5 mg\u002Fkg by mouth and parental presence; or\n3. parental presence alone.",[242],"Anesthesia Induction",{"date":222,"type":40},{"date":245,"type":40},"2024-04-16",{"date":247,"type":21},"2027-05-22",{"name":46,"class":47},{"id":250,"slug":4,"hasResults":11,"nctId":251,"briefTitle":252,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":56,"sex":16,"minAge":254,"maxAge":4,"enrollmentInfo":255,"targetDuration":4,"studyType":190,"phases":4,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":48},"100641309","NCT07660887","Olfactory Dysfunction in Aging Adults","Inclusion Criteria:\n\n* Age: 50 years or older\n* Ability to follow instructions and understand consent process in English\n* Adequate visual, auditory, or motor functioning to complete items in the test battery or availability of assistance or assist devices to complete tasks\n\nExclusion Criteria:\n\n\\- Vulnerable populations including prisoners or institutionalized individuals","50 Years",{"count":256,"type":21},500,"This prospective longitudinal cohort study will enroll adults aged 50 years and older to characterize olfactory dysfunction in aging. Participants will undergo comprehensive olfactory testing, cognitive assessment, biomarker collection, and imaging to identify clinically relevant phenotypes based on anatomic site of dysfunction. The study will also evaluate the impact of olfactory dysfunction on quality of life and identify baseline factors associated with changes in olfactory function over time.",[259],"Olfactory Dysfunction","2026-06-16",{"date":222,"type":40},{"date":263,"type":21},"2027-04-01",{"date":265,"type":21},"2032-04-30",{"name":46,"class":47},{"id":268,"slug":4,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":273,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":278,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":285,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":291},"100621356","NCT07369557","Mindfulness Training During Accelerated TMS for Depression","MB-TBS: Mindfulness-Based Theta-Burst Stimulation-A Pilot Study Integrating Mindfulness Training Into Accelerated Neuromodulation Therapy for Depression","Inclusion Criteria:\n\n* Clinical diagnosis of MDD and eligible for aiTBS at MUSC\n* Already enrolled in aiTBS course at MUSC\n* English proficiency\n* Smartphone or willingness to use study-provided device\n\nExclusion Criteria:\n\n* TMS contraindications (e.g., seizure history, implants, pregnancy)\n* Concurrent neuromodulation (ECT, VNS)\n* Psychotic disorder, bipolar disorder, active substance use disorder, high suicide risk\n* Unable\u002Funwilling to engage in mindfulness or complete questionnaires","80 Years",{"count":20,"type":21},[24],"This NIH-funded single-arm pilot tests the feasibility, acceptability, and preliminary effects of embedding brief guided mindfulness practice (via the Waking Up smartphone app) into the inter-session intervals of clinically administered accelerated intermittent theta-burst stimulation (aiTBS) for major depressive disorder (MDD). Participants receive aiTBS as standard clinical care at MUSC; the research intervention is daily guided mindfulness practice during the aiTBS course. Outcomes include feasibility\u002Facceptability, changes in state mindfulness and hedonic tone (Day 0 to Day 5), perceived ease of meditation, trait mindfulness at 4 and 12 weeks, and durability of antidepressant response (PHQ-9) at 4 and 12 weeks.",[30],[279,280,281,282,283,284],"Major Depressive Disorder","Transcranial Magnetic Stimulation","Theta-Burst Stimulation","Mindfulness","Positive Affect","Hedonic Tone",{"date":220,"type":40},{"date":287,"type":40},"2026-04-13",{"date":289,"type":21},"2026-10-30",{"name":46,"class":47},2,{"id":293,"slug":4,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":306,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":48},"100576209","NCT06782321","Emotional Recovery Post-Stroke","Centering Emotional Recovery Post-Stroke","eWELL","Inclusion Criteria:\n\n* Self-reported stroke-related deficits in emotional wellness such as anxiety, sleep disturbance, dread, fear, loss of hope, sadness.\n* Have experienced ischemic or hemorrhagic stroke at least 30 days prior\n* Stroke-related aphasia and\u002For upper extremity hemiparesis\n* Aged 21 years or older\n* English as primary language\n* Have corrected vision to be able to read text on a screen\n* Able to participate fully in the study's tele-rehabilitation (Aim 1) and\u002For virtual group programing (Aim 2) with personally owned device (i.e., phone, tablet, or laptop) and personal Wi-Fi connection or cellular service\n* Cognitive, language, and motor capacity to participate fully in the study's assessment session as per the judgment of the licensed, experienced stroke tele-rehabilitation occupational or speech therapist\n\nExclusion Criteria:\n\n* Unable to follow 1-2 step instructions given by the study team member during the informed consent procedures.\n* Pain that interferes with ability to participate in the study's upper extremity movement tasks.\n* Have impaired decision making capacity as determined by the U-ARE protocol for assessing capacity to provide informed consent.",{"count":300,"type":21},80,[24],"The purpose of this study is to evaluate whether adding an emotional wellness component to occupational therapy (OT) and\u002For speech therapy (ST) telerehabilitation improves overall emotional well-being and activity participation for people with stroke.",[304,305],"Stroke","Mental Health Wellness 1",[307,304,308],"Rehabilitation Studies","Stroke Recovery",{"date":310,"type":40},"2026-06-18",{"date":312,"type":40},"2025-05-01",{"date":314,"type":21},"2027-12",{"name":46,"class":47},{"id":317,"slug":4,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":322,"maxAge":273,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":329,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":48},"100293596","NCT03101917","Microtable® Method for Cochlear Implantation Investigational Device Exemption (IDE)","Microtable® Microstereotactic Frame and Drill Press and Associated Method for Cochlear Implantation","Inclusion Criteria:\n\n* Male or female 22 to 80 years of age.\n* Able to complete study related procedures.\n* Able to provide written informed consent.\n* Eligible for cochlear implant surgery as per routine pre-operative CI evaluation\u002Fworkup. If patient is a candidate for bilateral CI, the research technique will be performed unilaterally on the side with the most favorable anatomy and\u002For worst residual hearing.\n* Pre-operative CT scan of head\u002Ftemporal bone as part of routine care showing normal temporal bone and intra-cochlear anatomy.\n* Scheduled to receive either a Cochlear CI522 with the slim straight electrode or a MED-EL Synchrony with standard, Flex 24, or Flex 28 electrode.\n\nExclusion Criteria:\n\n* Females who are pregnant. As part of routine pre-operative care, all females of childbearing potential will undergo either urine or blood pregnancy testing.\n* ASA (American Society of Anesthesiologists) Physical Status classification of 4 or above or determined by surgeon to be too great of a health risk.\n* Previous mastoidectomy on the ear undergoing research procedures.\n* Severe anatomical abnormality of the temporal bone including but not limited to: 1) Mondini malformation 2) common cavity malformation 3) enlarged vestibular aqueducts (EVA) and\u002For 4) cochlea ossification.\n* Severe chronic ear disease.\n* Active middle ear infection.\n* Subjects without a favorable trajectory based on pre-operative imaging, analysis and planning with favorable trajectory defined as a linear track extending from the surface of the mastoid cortex, through the facial recess, and targeting the basal turn of the cochlea without violation of the external auditory canal, sigmoid sinus, tegmen, and\u002For facial nerve.","22 Years",{"count":324,"type":21},12,[24],"The Microtable® Microstereotactic Frame and Drill Press and Associated Method for Cochlear Implantation consists of a patient-customized microstereotactic frame which targets the cochlea. The intended use of the device in this early feasibility study is to surgically access the cochlea, allowing placement of an intra-cochlear electrode array for cochlear implantation, thereby providing a less invasive surgical option than currently performed. Compared to traditional cochlear implantation (CI) surgery, the investigators hypothesize that the minimally invasive, image-guided approach may offer the following benefits: (1) shorter procedure time including shorter general anesthesia time, (2) less tissue removal potentially eliminating post-operative mastoid bone depression, decreased post-operative patient discomfort, and quicker wound healing, (3) better chance of preservation of taste secondary to preservation of the chorda tympani nerve, and (4) standardization of electrode placement potentially allowing more consistent placement within the scala tympani sub-compartment of the cochlea which has been shown to be associated with improved post-operative audiological performance. This early feasibility study will focus on the advantages of the new technology to the patient. Advantages to the healthcare delivery system will be examined during the pivotal study phase.",[328],"Hearing Loss, Cochlear",{"date":310,"type":40},{"date":331,"type":21},"2027-07-01",{"date":333,"type":21},"2028-07-31",{"name":46,"class":47},{"id":336,"slug":4,"hasResults":11,"nctId":337,"briefTitle":338,"officialTitle":339,"acronym":340,"eligibilityCriteria":341,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":342,"enrollmentInfo":343,"targetDuration":4,"studyType":22,"phases":345,"briefSummary":346,"conditions":347,"keywords":350,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":355,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":358,"leadSponsor":360,"locationsCount":4},"100641404","NCT07658365","Olfactory Transcranial Focused Ultrasound","Modulation of Olfactory Valence by Transcranial Focused Ultrasound (tFUS)","O-tFUS","Inclusion Criteria:\n\n* Age 18-65 years\n* Healthy adult volunteers\n* Normal olfactory function (Sniffin' Sticks total TDI ≥ 30.75)\n* Ability to provide informed consent\n* English fluency sufficient for task completion\n\nExclusion Criteria:\n\n* MRI or tFUS contraindications (e.g., metal implants, claustrophobia, pregnancy)\n* Sinonasal conditions affecting airflow or smell\n* Current use of medications that alter olfaction\n* Positive urine drug screen","65 Years",{"count":344,"type":21},28,[24],"This study investigates the causal effects of low-intensity transcranial focused ultrasound (tFUS) on odor valence perception and odor-elicited avoidance behaviors in healthy adults. Participants undergo sham and active tFUS targeting the amygdala (AMYG) and ventral striatal olfactory tubercle (VSOT) in a within-subject, randomized, sham-controlled crossover design. Outcomes include subjective odor ratings and objective neurophysiological and behavioral indices of odor valence processing. This research is exploratory and mechanistic in nature and is not intended to evaluate clinical safety or therapeutic efficacy.",[348,349],"Healthy","Olfaction",[351,352,353,354],"healthy volunteer","electroencephalography (EEG)","magnetic resonance imaging (MRI)","odors","2026-06-15",{"date":222,"type":40},{"date":156,"type":21},{"date":359,"type":21},"2028-04-30",{"name":46,"class":47},{"id":362,"slug":4,"hasResults":11,"nctId":363,"briefTitle":364,"officialTitle":365,"acronym":4,"eligibilityCriteria":366,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":342,"enrollmentInfo":367,"targetDuration":4,"studyType":22,"phases":369,"briefSummary":370,"conditions":371,"keywords":373,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":48},"100514357","NCT05977439","RECOVERS - Realigning Emotion and COgnition Via prEcision Regulation networkS","A Multiphase Program of Multimodal Computational Modeling and Hybrid Interventions Including EEG-Synchronized Transcranial Magnetic Stimulation and Cognitive Behavioral Therapy","Study 1 (Healthy Participants)\n\nInclusion Criteria:\n\n* Age 18-65 years\n* Medically and psychiatrically healthy with no history of psychiatric or neurological disorders\n* English-speaking\n* Capacity to provide informed consent\n* Willingness and ability to complete study procedures\n* Negative pregnancy test for participants of childbearing potential\n\nExclusion Criteria:\n\n* Any current or past psychiatric diagnosis\n* Neurological disorders or history of central nervous system disease\n* History of seizure or epilepsy or use of medications that lower seizure threshold\n* Significant head injury or loss of consciousness\n* Implanted metal or contraindications to MRI or TMS\n* Substance use disorder (excluding nicotine or caffeine)\n* Pregnancy or plans to become pregnant during study participation\n* Inability to complete study procedures\n\nStudies 2, 3, and 4 (Participants with Depression)\n\nInclusion Criteria:\n\n* Age 18-65 years\n* Current diagnosis of Major Depressive Disorder (MDD)\n* Depression severity consistent with study criteria (e.g., HAM-D ≥ 17)\n* No history of psychotic or bipolar disorders\n* English-speaking\n* Capacity to provide informed consent\n* Willingness and ability to complete study procedures\n* Negative pregnancy test for participants of childbearing potential\n\nExclusion Criteria:\n\n* Neurological disorders or history of central nervous system disease\n* History of seizure or epilepsy or use of medications that lower seizure threshold\n* Significant head injury or loss of consciousness\n* Implanted metal or contraindications to MRI or TMS\n* Substance use disorder (excluding nicotine or caffeine)\n* Current participation in another interventional clinical trial\n* Pregnancy or plans to become pregnant during study participation\n* Any condition that would interfere with safe participation or completion of study procedures",{"count":368,"type":21},120,[24],"In this research study, investigators examine how brain activity changes during tests of emotional processing, attention, and memory using multimodal neuroimaging methods including electroencephalography (EEG), functional magnetic resonance imaging (fMRI), and functional near-infrared spectroscopy (fNIRS). Transcranial magnetic stimulation (TMS) is used to probe and modulate brain networks related to cognitive flexibility and emotion regulation.\n\nThe study includes multiple related sub-studies involving healthy participants and participants with depression. Some study components focus on mechanistic modeling using non-therapeutic neurostimulation in healthy participants, while other components include interventional approaches such as individualized EEG-synchronized repetitive TMS (rTMS), cognitive tasks, and brief cognitive behavioral therapy (CBT) in participants with depression. Certain study components also evaluate CBT alone without TMS to assess behavioral intervention effects.",[30,279,372],"Suicidal Ideation",[374,375,376,377,378,379,380],"transcranial magnetic stimulation","EEG-synchronized rTMS","closed-loop neurostimulation","depression","suicide prevention","cognitive behavioral therapy (CBT)","neuroplasticity","2026-06-12",{"date":260,"type":40},{"date":384,"type":40},"2024-02-01",{"date":386,"type":21},"2028-10-01",{"name":46,"class":47},{"id":389,"slug":4,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":16,"minAge":394,"maxAge":395,"enrollmentInfo":396,"targetDuration":4,"studyType":22,"phases":398,"briefSummary":399,"conditions":400,"keywords":402,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":48},"100634156","NCT07536022","At-home taVNS for Neurorehabilitation in Parkinson's Disease","Developing At-home taVNS for Neurorehabilitation in Parkinson's Disease","Inclusion Criteria:\n\n* Issues with walking, balance, and gait as determined by a movement disorders neurologist (a score of equal to or greater than 1 on MDS-UPDRS items 2.12 (walking and balance), and 3.10 (gait))\n* Diagnosis of idiopathic Parkinson's Disease based on UK Brain Bank diagnostic criteria\n* Hoehn and Yahr Stage 2-4 as determined by a movement disorders neurologist\n* Stable on dopaminergic medications over the past 30 days prior to enrollment in the study\n\nExclusion Criteria:\n\n* A history of taVNS in the last 6 months\n* A history of brain surgery, traumatic brain injury or stroke\n* Diagnosis of a nervous system disorder besides PD, alcohol or substance use disorder, or unstable cardiovascular conditions\n* History of myocardial infarction or arrhythmia, bradycardia\n* A history of other significant gait impairment unrelated to PD (e.g. orthopedic deformities)\n* Inability to complete gait\u002F motor assessments (without assistance or assistance devices)\n* Ear trauma, facial pain, anatomical abnormalities or other barriers preventing earpiece fit\n* Failure to meet all criteria on a standardized MRI\u002FtaVNS safety screening: This includes, but is not limited to, the presence of claustrophobia, implanted electronic devices that are not 3T MRI compatible (e.g., pacemakers), metallic objects or fragments (e.g., bullets), and non-removable hair clips or piercings.\n* Individuals with a diagnosis of cognitive impairment (MoCA \\\u003C 24) that would make them unable to understand and follow study instructions or to consent for themselves.\n* Pregnancy\n* Visual hallucinations or other psychotic symptoms, other than mild visual hallucinations secondary to PD medications, not requiring treatment, or well controlled on stable doses of quetiapine or pimavenserin.\n* Individuals with a history of seizure(s)\n* Inability to perform at-home taVNS procedures safely and properly (either alone or with the aid of a caregiver)\n* Uncorrected visual or hearing impairments that would impact performance on cognitive tests or ability to follow study procedures\n* Use of B-Blockers, dopamine blocking agent (other than quetiapine or pimavenserin in stable doses), antiarrhythmic medication, acetylcholine esterase inhibitor (study doctor will consider if on stable doses), midodrine, fludrocortisone, droxidopa, or anticholinergic drugs","40 Years","85 Years",{"count":397,"type":21},16,[24],"The goal of this clinical trial is to learn if taVNS works to treat symptoms of Parkinson's Disease in adults. It will also learn about the feasibility and preliminary efficacy of taVNS administered at home by the participant.\n\nThe main questions it aims to answer are:\n\n1. Is at-home taVNS feasible and effective for treating symptoms of Parkinson's Disease? How often are participants completing the stimulation protocol? What are the side effects of stimulation experienced by participants? How do participants rate the experience of taVNS sessions at home? How do participants' scores on assessments and questionnaires change with taVNS treatments?\n2. How does taVNS impact connections between neural networks in the brain of patients with Parkinson's Disease at rest?\n\nParticipants will:\n\n* Have a baseline MRI scan to take images of their brain.\n* Complete a series of assessments and questionnaires to evaluate their Parkinson's Disease motor symptoms, cognitive and neuropsychiatric symptoms, and other non-motor symptoms.\n* Have an initial taVNS session where their threshold to perceive the stimulation will be measured. This value will be used to stimulate each participant at a specific dose relative to their individual perception of stimulation.\n* Be trained on how to use the taVNS device and system and have one 1-hour taVNS session where their vitals will be monitored.\n* Self-administer 1-hour daily taVNS sessions for 8 weeks at-home, complete tolerability questionnaires, and weekly remote check-ins with study staff.\n* After 4-weeks of at-home taVNS, participants will come in-person to repeat the questionnaires and assessments from the first visit.\n* Following the 8 weeks of taVNS sessions, participants will repeat the MRI scan, assessments and questionnaires from visit 1.\n* Participants will complete questionnaires remotely 1 month following their last taVNS sessions.",[401],"Parkinson's Disease",[401,403,404,405,406,407,408,409,410],"parkinsons","parkinson's","taVNS","transcutaneous vagus nerve stimulation","non-invasive brain stimulation","transcutaneous auricular vagus nerve stimulation","gait","motor symptoms","2026-06-11",{"date":355,"type":40},{"date":414,"type":40},"2026-06-01",{"date":416,"type":21},"2027-06",{"name":46,"class":47},{"id":419,"slug":4,"hasResults":11,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":4,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":424,"enrollmentInfo":425,"targetDuration":4,"studyType":22,"phases":427,"briefSummary":428,"conditions":429,"keywords":431,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":437,"startDateStruct":438,"completionDateStruct":439,"leadSponsor":441,"locationsCount":48},"100631676","NCT07503782","OEA for Young Adults With Alcohol Use Disorder","Investigating Oleoylethanolamide (OEA) as a Novel Multi-System Based Therapeutic for Young Adults With Alcohol Use Disorder","Inclusion Criteria:\n\n* Age 18 to 25.\n\nCall study team for additional screening and information.","25 Years",{"count":426,"type":21},42,[169],"The goal of this clinical trial is to evaluate the effects of oleoylethanolamide (OEA) supplementation on inflammation, the oral microbiome, neurocognitive function, and alcohol use in young adults ages 18 to 25 with alcohol use disorder (AUD). The main questions it aims to answer are:\n\n* Does OEA reduce peripheral markers of immune activation (IL-6, TNF-α, IL-1β, and LPS)?\n* Does OEA alter oral microbiome composition?\n* Does OEA improve neurocognitive measures of reward sensitivity and impulsivity?\n\nResearchers will compare OEA to a placebo (a look-alike substance with no active ingredient) to determine whether OEA improves biological and behavioral outcomes associated with AUD.\n\nParticipants (N = 42) will:\n\n* Be randomly assigned to receive 300mg TRIPTI (providing 250 mg\u002Fday of OEA) or placebo for 6 weeks.\n* Provide blood, saliva, and urine samples\n* Complete cognitive testing and questionnaires\n* Report alcohol use during the study\n* Attend in-person study visits for monitoring and assessments\n\nThis randomized, double-blind, placebo-controlled pilot trial will provide preliminary data on the potential efficacy of OEA as a multi-system intervention for young adults with AUD.",[430],"Alcohol Use Disorder (AUD)",[432,433,434,435,436],"OEA","oleoylethanolamide","AUD","Oral microbiome","Alcohol",{"date":355,"type":40},{"date":203,"type":21},{"date":440,"type":21},"2031-03-31",{"name":46,"class":47},{"id":443,"slug":4,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":445,"acronym":4,"eligibilityCriteria":446,"healthyVolunteers":11,"sex":447,"minAge":17,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":22,"phases":450,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":461,"leadSponsor":463,"locationsCount":48},"100595643","NCT07035119","Transcranial Magnetic Stimulation for Chronic Scrotal Content Pain","Inclusion Criteria:\n\n* Male patients with chronic scrotal pain lasting for 6 or more months.\n* Pain must be present 3 or more days of the week.\n\nExclusion Criteria:\n\n* No new pain medications within the last 30 days.","MALE",{"count":449,"type":21},50,[216,169],"The purpose of this study is to perform an open label feasibility trial of TMS for the treatment of chronic scrotal content pain.",[453],"Scrotal Pain",[455,456,457],"Scrotal pain","testicular pain","Transcranial magnetic stimulation","2026-06-10",{"date":411,"type":40},{"date":177,"type":21},{"date":462,"type":21},"2030-04-01",{"name":46,"class":47},{"id":465,"slug":4,"hasResults":11,"nctId":466,"briefTitle":467,"officialTitle":468,"acronym":469,"eligibilityCriteria":470,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":394,"enrollmentInfo":471,"targetDuration":4,"studyType":22,"phases":473,"briefSummary":474,"conditions":475,"keywords":478,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":488},"100568999","NCT06688539","E-cigarette Cessation in Adults Who Co-use Cannabis","A Prospective Trial of Varenicline and Incentives for E-cigarette Cessation in Adults Who Co-use Cannabis","VapeCAT","Inclusion Criteria:\n\n* Between the ages of 18 and 40 years old\n* Use e-cigarettes daily or near daily in the past month\n* Must submit a positive instant-read urine cotinine test at screening (≥ 200 ng\u002Fml)\n* Be interested in quitting use of e-cigarettes\n* Must be willing to take varenicline for the standard 12-week course of treatment\n* Self-reported use of cannabis on at least 10 out of the past 30 days or must submit a positive qualitative urinary cannabinoid test at screening (\\> 50 ng\u002Fml)\n\nExclusion Criteria:\n\n* Any serious or unstable medical\u002Fpsychiatric disorder (including severe substance use disorders, other than cannabis or tobacco use disorders) in the past three months that may interfere with study performance\n* Use of cigarettes on 10+ days in the past 30\n* Currently pregnant or breastfeeding\n* Current use of medications with smoking cessation efficacy\n* Use of any medications that would interfere with varenicline",{"count":472,"type":21},105,[239],"The purpose of this study is to better understand tobacco outcomes using a commonly prescribed stop smoking medication (varenicline) and financial incentives for adults who also use cannabis. Varenicline is not FDA approved for e-cigarette cessation, but is FDA approved for cigarette cessation. Investigators are also interested in how cannabis\u002Fmarijuana and tobacco interact during a tobacco quit attempt. All participants will receive e-cigarette cessation treatment for 12 weeks. To qualify, participants must be between the ages of 18-40 and use both e-cigarettes and cannabis. Participants do not need to be interested in quitting cannabis to qualify. This study is being conducted at three sites: the Medical University of South Carolina in Charleston, SC, Behavioral Health Services in Pickens, SC, and MUSC Lancaster in Lancaster, SC.",[476,477],"Nicotine Dependence","Tobacco Use Disorder",[479,480,481],"e-cigarettes","cannabis","treatment",{"date":381,"type":40},{"date":484,"type":40},"2025-02-19",{"date":486,"type":21},"2027-06-01",{"name":46,"class":47},3,{"id":490,"slug":4,"hasResults":11,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":494,"eligibilityCriteria":495,"healthyVolunteers":56,"sex":16,"minAge":17,"maxAge":424,"enrollmentInfo":496,"targetDuration":4,"studyType":22,"phases":498,"briefSummary":499,"conditions":500,"keywords":501,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":506,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":48},"100534478","NCT06239350","Young Adult Tobacco\u002FNicotine and Cannabis Co-use","The Impact of Cannabis and Tobacco\u002FNicotine Product Co-use in Young Adults: Prospective Cessation Evaluation and Substitution","YouthCAT","Inclusion Criteria:\n\n* Between the ages of 18 and 25 years old\n* Must use at least one nicotine or tobacco product (nicotine vaping and\u002For cigarettes) on at least 20 out of the past 30 days for at least the past 3 months\n* Must express interest in nicotine cessation (all products)\n* Must submit a positive instant-read, oral fluid cotinine sample prior to enrollment\n* Must report use of cannabis on at least 10 out of the past 30 days\n* Must submit a positive instant-read cannabinoid test prior to enrollment\n* Must be able to provide informed consent\n\nExclusion Criteria:\n\n* Any significant or acutely unstable medical, psychiatric, or substance use problem that would contraindicate research, interfere with safety, compromise data integrity, or preclude consistent study participation\n* Pregnant (self-report) or trying to become pregnant\n* Self-reported use of medications with smoking cessation efficacy\n* Immediate interest in cannabis cessation or treatment",{"count":497,"type":21},350,[24],"The goal of this project is to better understand the relationship between tobacco\u002Fnicotine and cannabis using behavioral economics during a tobacco\u002Fnicotine quit attempt. All participants will receive tobacco\u002Fnicotine cessation treatment (smoking and\u002For vaping treatment) for 12 weeks. To qualify, participants must be between the ages of 18-25 and use tobacco products (smoke cigarettes and\u002For vape nicotine) and use cannabis (in any form). Participants do not need to be interested in quitting cannabis\u002Fmarijuana to qualify. This study is being conducted by the Medical University of South Carolina. All procedures are conducted remotely and there is no in-person visits are needed.",[477,476],[502,503,504,505],"tobacco","vaping","cessation","cannabis\u002Fmarijuana",{"date":381,"type":40},{"date":508,"type":40},"2024-05-13",{"date":510,"type":21},"2028-01-03",{"name":46,"class":47},{"id":513,"slug":4,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":517,"eligibilityCriteria":518,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":22,"phases":521,"briefSummary":522,"conditions":523,"keywords":528,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":529,"lastUpdatePostDateStruct":530,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":48},"100501644","NCT05811936","The SNAP Tool for Head and Neck Cancer Survivor-Caregiver Dyads","A Randomized Controlled Trial to Evaluate the Survivorship Needs Assessment Planning (SNAP) Tool for Head and Neck Cancer Survivor-Caregiver Dyads","SNAP","Patient Inclusion Criteria:\n\n1. Age \\>18\n2. Stage I-IV non-metastatic HNC (i.e., lip\u002Foral cavity, nasopharynx, salivary gland, oropharynx, hypopharynx, paranasal sinus, larynx and cutaneous cancers)\n3. Currently receiving radiation treatment (with\u002Fwithout surgery and\u002For concurrent chemotherapy) with curative intent\n4. Able to nominate caregiver, the primary support person, also interested in participating\n\nCaregiver Inclusion Criteria:\n\n1. Age \\>18\n2. Provide care for a loved one with stage I-IV HNC\n3. Agrees to participate after being nominated\n\nPatient Exclusion Criteria:\n\n1. Patients who do not read\u002Funderstand English\n2. Patients who are cognitively impaired and cannot complete interviews as judged by the referring health care provider\n3. Patients concurrently diagnosed with and\u002For receiving treatment for a second \"significant\" primary cancer, except the following:\n\n   * Excised and cured non-melanoma skin cancer\n   * Carcinoma in situ of breast or cervix\n   * Superficial bladder cancer\n   * Stage 1 differentiated thyroid cancer that is resected or observed\n   * pT1a\u002FpT1b prostate cancer comprising \\\u003C5% of resected tissue with normal prostate specific antigen (PSA) since resection\n   * cT1a\u002FcT1b prostate cancer treated with brachytherapy\n\nCaregiver Exclusion Criteria:\n\n1. Inability to read or understand English\n2. Cognitively impaired and cannot complete interviews, as judged by the referring health care provider",{"count":520,"type":21},352,[24],"In this randomized behavioral intervention, head and neck cancer (HNC) survivors and their caregivers (N=176 HNC survivor-caregiver dyads) will be randomized to either Survivorship Needs Assessment Planning (SNAP) or Usual Care (UC) groups to examine the effects of SNAP on outcomes. SNAP includes two sessions with a needs assessment and tailored care plan and a supportive mobile app after completion of radiation to promote uptake of recommended medical and supportive care. The study aims to evaluate the effects of SNAP on symptom severity in patients and caregiver burden in caregivers. Secondary outcomes include psychological distress (anxiety and depression), healthcare utilization (receipt of recommended care) and unmet needs and self-efficacy in HNC survivor-caregiver dyads. Participants will complete surveys at baseline, 6 months, and 9 months post randomization with validated PROMs, and receive intervention modules at the end of radiation and month 3. Participants in the SNAP group will also receive mobile app support.",[524,525,526,527],"Head and Neck Cancer","Survivorship","Caregiver Burden","Head and Neck Neoplasms",[524,525],"2026-06-09",{"date":411,"type":40},{"date":532,"type":40},"2023-08-23",{"date":534,"type":21},"2027-12-31",{"name":46,"class":47},{"id":537,"slug":4,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":11,"sex":542,"minAge":17,"maxAge":4,"enrollmentInfo":543,"targetDuration":4,"studyType":22,"phases":545,"briefSummary":546,"conditions":547,"keywords":548,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":554,"startDateStruct":555,"completionDateStruct":556,"leadSponsor":558,"locationsCount":4},"100634435","NCT07539649","LiveWell mBc: Adapted Dialectical Behavioral Therapy Skills Training","LiveWell mBC: Pilot Test of an Adapted Dialectical Behavioral Therapy Skills Training Program in Groups of Women Living With Metastatic Breast Cancer","Inclusion Criteria:\n\n1. identify as female\n2. be diagnosed with metastatic (AJCC stage IV) breast cancer\n3. be receiving care for metastatic breast cancer at Hollings Cancer Center\n4. endorse \\>3 out of 10 on the NCCN distress thermometer over the past week plus at least one emotional concern on the problem checklist\n5. be \\> 18 years of age\n6. be able to understand, speak, and read English\n7. be able to provide informed consent.\n\nExclusion Criteria:\n\n1. reported or suspected cognitive impairment\n2. presence of untreated serious mental illness (e.g., schizophrenia) indicated by the medical chart or treating oncologist\n3. expected survival \\\u003C6 months, as indicated by a hospice referral","FEMALE",{"count":544,"type":21},48,[24],"In this pilot randomized controlled trial, women with metastatic breast cancer and at least mild distress (N=48) will be randomized to receive LiveWell mBC, a group-based adapted Dialectical Behavioral Therapy (DBT) Skills Training protocol, or Usual Care. The investigators will evaluate feasibility, acceptability, and preliminary efficacy of LiveWell to reduce distress (primary outcome) and improve psychological well-being, symptom burden, and quality of life (secondary outcomes).",[525],[549,550,551,552],"Dialectical Behavioral Therapy","Metastatic Breast Cancer","Distress","Psychosocial Oncology","2026-06-08",{"date":458,"type":40},{"date":203,"type":21},{"date":557,"type":21},"2027-01-31",{"name":46,"class":47},{"id":560,"slug":4,"hasResults":11,"nctId":561,"briefTitle":562,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":22,"phases":565,"briefSummary":566,"conditions":567,"keywords":568,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":571,"startDateStruct":572,"completionDateStruct":573,"leadSponsor":575,"locationsCount":4},"100606614","NCT07177846","LiveWell: An Adapted Dialectical Behavioral Therapy Skills Training Protocol for Patients Living With Metastatic Lung Cancer","Inclusion Criteria:\n\n* Age ≥ 18\n* AJCC Stage IV non-small cell lung cancer\n* Receiving treatment with non-curative intent\n* English proficiency\n* Able to provide informed consent\n* National Comprehensive Cancer Network distress screening score ≥ 3\u002F10\n\nExclusion Criteria:\n\n* Cognitive impairment\n* Untreated serious mental illness\n* Expected survival \\\u003C 6 months",{"count":300,"type":21},[24],"In this pilot randomized controlled trial, patients with metastatic non-small cell lung cancer and at least mild distress (N=80) will be randomized to receive LiveWell, an adapted Dialectical Behavioral Therapy (DBT) Skills Training protocol) or Usual Care. The investigators will evaluate feasibility, acceptability, and preliminary efficacy of LiveWell to reduce distress (primary outcome) and improve psychological well-being, symptom burden, and quality of life (secondary outcomes). The investigators will explore emotion regulation as a potential mechanism of change.",[525],[549,552,569,570],"Lung Cancer","Psychological Distress",{"date":458,"type":40},{"date":92,"type":21},{"date":574,"type":21},"2028-03-01",{"name":46,"class":47},{"id":577,"slug":4,"hasResults":11,"nctId":578,"briefTitle":579,"officialTitle":580,"acronym":4,"eligibilityCriteria":581,"healthyVolunteers":11,"sex":16,"minAge":235,"maxAge":582,"enrollmentInfo":583,"targetDuration":4,"studyType":22,"phases":585,"briefSummary":586,"conditions":587,"keywords":591,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":553,"lastUpdatePostDateStruct":594,"startDateStruct":595,"completionDateStruct":597,"leadSponsor":599,"locationsCount":48},"100590141","NCT06963554","Examining Whether Project Support Works","Randomized Controlled Trial of Project Support","Inclusion Criteria:\n\n* Family is seeking trauma-focused services for their child;\n* Child is between 6 - 13 years old;\n* Caregiver agreed to be contacted for volunteer research opportunities;\n* Caregiver and child can communicate in English or Spanish;\n* Child has been living with caregiver for the last 6 months or longer;\n* Family is able to participate in services delivered via telehealth.\n\nExclusion Criteria:\n\n* Child or caregiver has a diagnosis that would impair their ability to participate in or benefit from services (e.g., traumatic brain injury, developmental disability, psychosis);\n* Child is in Foster Care or Department of Social Services custody;\n* The caregiver is unwilling or unable to give informed consent and\u002For the child is unwilling and unable to give assent.","13 Years",{"count":584,"type":21},100,[24],"This study will involve a randomized, controlled trial with two parallel groups, Project Support and a treatment as usual control group. Families with a child on the waitlist for trauma-focused services will be invited to participate. Participation involves completing a baseline assessment of family functioning and trauma characteristics. Participants will then be randomized to either Project Support or the treatment as usual control group. All participants will be invited to complete the post-test assessment 4-6 weeks after the baseline assessment, prior to beginning trauma-focused services.",[588,589,590],"Parent-Child Relations","Parenting Self Efficacy","Child Mental Health",[592,593],"Child trauma","Non-offending caregiver",{"date":529,"type":40},{"date":596,"type":40},"2025-11-04",{"date":598,"type":21},"2028-03-31",{"name":46,"class":47},""]